Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Model‐informed drug development (MIDD) was central to the development of the oral proteasome inhibitor ixazomib, facilitating internal decisions (switch from body surface area (BSA)‐based to fixed dosing, inclusive phase III trials, portfolio prioritization of ixazomib‐based combinations, phase III...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Hanley, Michael J., Diderichsen, Paul M., Yang, Huyuan, Ke, Alice, Teng, Zhaoyang, Labotka, Richard, Berg, Deborah, Patel, Chirag, Liu, Guohui, van de Velde, Helgi, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585617/
https://www.ncbi.nlm.nih.gov/pubmed/29446068
http://dx.doi.org/10.1002/cpt.1047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585617/
https://www.ncbi.nlm.nih.gov/pubmed/29446068
http://dx.doi.org/10.1002/cpt.1047

Ejemplares similares